# The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT

(This document is based on the provisions contained in the legislation as of the latest date listed below.)

	Prepared B	y: The Professional S	taff of the Committe	ee on Health Policy
BILL:	SB 824			
INTRODUCER:	Senators Joyner and Flores			
SUBJECT:	Hepatitis C Testing			
DATE:	March 14, 2014	REVISED:		
ANAL	YST :	STAFF DIRECTOR	REFERENCE	ACTION
. Lloyd	St	ovall	HP	Pre-meeting
2.			JU	
3.			AHS	
ļ.			AP	

## I. Summary:

SB 824 creates a Hepatitis C testing program under s. 381.0044, F.S., and requires certain health care practitioners to offer Hepatitis C screening tests to individuals born between January 1, 1945 and December 31, 1965. Screening is to be offered to persons who receive services as an inpatient in a general hospital or primary care services in a hospital inpatient or outpatient setting or from a physician, physician assistant or nurse practitioner. For designated individuals, a health care provider is not required to offer the screening test.

If a person accepts a screening test offer and receives a positive result, the bill requires the health care practitioner to offer the patient follow-up care or a referral. Follow-up care must include a Hepatitis C diagnostic test.

The Department of Health (DOH) is required to adopt rules to provide procedures for how to offer the tests and the State Surgeon General must submit an evaluation of the effectiveness of the program by January 1, 2016. The report is due to the Governor, President of the Senate, the Speaker of the House of Representatives, and the chairs of the appropriate substantive committees.

### II. Present Situation:

"Hepatitis" means inflammation of the liver and is also the name of a family of viral infections that affect the liver. The most common types are Hepatitis A, Hepatitis B, and Hepatitis C. Most people infected with the Hepatitis C (HCV) have no symptoms and are unaware that they have the disease until liver damage is discovered years later. The HCV can either be an acute or

<sup>&</sup>lt;sup>1</sup> Centers for Disease Control and Prevention, *Hepatitis C Information for the Public*, <a href="http://www.cdc.gov/hepatitis/C/cFAQ.htm#statistics">http://www.cdc.gov/hepatitis/C/cFAQ.htm#statistics</a> (last visited Mar. 14, 2014).

chronic infection. The virus can last a lifetime and lead to serious liver problems.<sup>2</sup> Hepatitis C-related end-state liver disease is the most common indication for liver transplants among American adults, accounting for more than 30 percent of cases.<sup>3</sup>

The virus is passed through contact with contaminated blood. A person's risk of an infection is increased if the individual has one of the following risk factors:

- Is a health care worker who has been exposed to infected blood, such as through an infected needle that pierced the skin;
- Injects or previously injected illicit drugs;
- Has HIV;
- Receives a piercing or tattoo in an unclean environment using unsterile equipment;
- Received a blood transfusion or organ transplant before 1992;
- Received clotting factor concentrates before 1987:
- Received hemodialysis treatments for a long period of time; or,
- Was born to a woman with a Hepatitis C infection.<sup>4</sup>

It is estimated that at least 3.2 million persons in the United States, including more than 310,000 Floridians, have the Hepatitis C virus infection, and most of those have chronic infections. <sup>5,6</sup> Approximately 23,000 chronic cases of the HCV infection is reported each year in Florida <sup>7</sup>. However, because the initial stages of the HCV infection are either asymptomatic or associated only with mild symptoms, most new infections are undiagnosed.

The Centers for Disease Control and Prevention (CDC) estimates that although persons born during the 1945 - 1965 period, the "baby boomers," comprise an estimated 27 percent of the population, they account for approximately 75 percent of all HCV infections in the United States, 73 percent of HCV-associated mortality, and are at the greatest risk for HCV-related disease. In 2012, the CDC issued new recommendations that all adults born during this time period should undergo one-time testing regardless of their risk status. Estimates indicate that as many as 5 million Floridians fall into the baby boomer cohort.

The United States Preventive Services Task Force (USPSTF) in June 2013 added, as a B-rating, a recommendation that a one-time screening for HCV infection be offered for adults born between 1945 and 1965. The USPSTF in its recommendation statement concluded that persons

<sup>&</sup>lt;sup>2</sup> *Id*.

<sup>&</sup>lt;sup>3</sup> United States Preventive Services Task Force, Screening for Hepatitis C Virus Infection in Adults, U.S. Preventive Services Task Force Recommendation Statement (June 25, 2013),

http://www.uspreventiveservicestaskforce.org/uspstf12/hepc/hepcfinalrs.htm (last visited Mar. 14, 2014).

<sup>&</sup>lt;sup>4</sup> Mayo Clinic, *Diseases and Conditions - Hepatitis C*, <a href="http://www.mayoclinic.org/diseases-conditions/hepatitis-c/basics/risk-factors/con-20030618">http://www.mayoclinic.org/diseases-conditions/hepatitis-c/basics/risk-factors/con-20030618</a> (last visited Mar. 14, 2014).

<sup>&</sup>lt;sup>5</sup> Centers for Disease Control and Prevention, *Supra*, note 1.

<sup>&</sup>lt;sup>6</sup> Department of Health, 2014 Agency Legislative Bill Analysis - SB 824 (January 7, 2014), on file with Senate Health Policy Committee.

<sup>&</sup>lt;sup>7</sup> *Id*.

<sup>&</sup>lt;sup>8</sup> Department of Health, *Supra* note 6 at 2.

<sup>&</sup>lt;sup>9</sup> United States Preventive Services Task Force, Supra, note 3.

<sup>&</sup>lt;sup>10</sup> United States Preventive Services Task Force, *Supra*, note 3. A B rating means the Task Force recommends the service and that there is a high certainty that the net benefit is moderate or that the net benefit is moderate to substantial. The practice

born during this time period are more likely to be diagnosed with HCV infection because they received blood transfusions before screening was introduced or have a history of other risk factors. A one-time screening may lead to earlier detection of the infection and result in increased diagnosis and treatment. Description of the infection and result in increased diagnosis and treatment.

## Florida's Hepatitis C Programs and Coverage

#### Department of Health

Currently, adult Floridians, aged 18 years and older, who test positive for HCV are offered the Hepatitis B vaccine and counselling on nutrition; exercise; stopping drug, alcohol and tobacco use; and other health messages by county health departments (CHD) through the statewide Hepatitis Prevention Program. (HPP). All of these interventions slow the progress of the HCV, but there is no vaccine for HCV. While HPP testing and vaccine are provided to CHDs at no charge, some CHDs charge a small administrative fee for the vaccines, usually not more than \$20. \(^{13}\) A CHD will waive the cost if the client cannot afford the fee.

Funding for specific hepatitis prevention programs is provided to 15 CHDs: Alachua, Bay, Broward, Collier, Duval, Escambia, Lee, Miami-Dade, Monroe, Okeechobee, Orange, Palm Beach, Pinellas, Polk, and Seminole. All CHDs are eligible to participate. <sup>14</sup> In fiscal year 2013-2014, the HPP received \$1,413,745 in General Revenue funding. Other annual funding supports the HPP from the HIV Prevention Program for viral hepatitis testing; HIV Patient Care Program for Hepatitis A and B vaccines and funds from the CDC for a hepatitis prevention coordinator and associated expenses. <sup>15</sup> The Department of Health's, Bureau of Epidemiology also funds and provides hepatitis surveillance and epidemiologic services.

The state laboratory processes all viral hepatitis tests for the HPP. In 2012, the laboratory performed 22,826 tests and of those, 9 percent were positive. <sup>16</sup> The HPP does not provide treatment for HCV.

#### Medicaid

Medicaid is a joint federal and state funded program that provides health care to low income Floridians. The program is administered by the Agency for Health Care Administration (AHCA) and financed with federal and state funds. Over 3.3 million Floridians are currently enrolled in Medicaid and the program's estimated expenditures for fiscal year 2012-2013 were approximately \$21 billion. The statutory authority for the Medicaid program is contained in ch. 409, F.S.

suggestion is to offer this service. The Task Force recommends that services be offered for A and B rated services, without further qualification.

<sup>&</sup>lt;sup>11</sup> *Id*.

<sup>12</sup> Id

<sup>&</sup>lt;sup>13</sup> Department of Health, *Supra*, note 6 at 2.

<sup>&</sup>lt;sup>14</sup> Department of Health, *Supra* note 6 at 2.

<sup>&</sup>lt;sup>15</sup> *Id*.

<sup>&</sup>lt;sup>16</sup> *Id*. at 3.

<sup>&</sup>lt;sup>17</sup> Agency for Health Care Administration, *Florida Medicaid*, <a href="http://ahca.myflorida.com/Medicaid/index.shtml">http://ahca.myflorida.com/Medicaid/index.shtml</a> (last visited Mar. 14, 2014).

Florida Medicaid covers medically necessary laboratory services for screening and diagnosis of Hepatitis C. Florida Medicaid also covers all medically necessary treatments for active Hepatitis C related illness for its recipients.

Medicaid recipients who test positive for the virus would likely have the confirming test and one or more other procedures to determine if the recipient has an active viral disease and to determine the quantity and characteristics of the virus. The estimated number of current Medicaid recipients within the "baby boomer" cohort is 301,776.<sup>18</sup>

# III. Effect of Proposed Changes:

**Section 1** creates s. 381.0044, F.S., relating to new Hepatitis C testing standards for certain health care practitioners and any person born between January 1, 1945 and December 31, 1965. The bill creates definitions specific to this section for:

- Health care practitioner;
- Hepatitis C diagnostic test; and,
- Hepatitis C screening test.

A person who falls within the designated age cohort and who receives health care services as an inpatient at a general hospital, primary care services in a hospital inpatient or outpatient setting, or from a physician, physician assistant or nurse practitioner, must be offered a Hepatitis C screening test.

A health care practitioner would not be required to offer a test if the health care practitioner reasonably believes the person:

- Is being treated for a life-threatening emergency;
- Has previously been offered a Hepatitis C test or has received a screening test; however, if the person's medical condition indicates the need for additional testing, a test should be offered; or,
- Lacks the capacity to consent to the test.

If a person receives a positive test result, the practitioner shall offer the person follow-up health care or refer the person to a health care provider that can provide follow-up health care. The DOH is directed to adopt rules for linguistically and culturally appropriate procedures for offering the Hepatitis C test.

The bill provides that its provisions do not impact the scope of practice of a health care practitioner or diminish the authority or professional obligation of a health care practitioner to offer a Hepatitis C screening or diagnostic test or to provide services or follow-up treatment.

The State Surgeon General is required to provide an evaluation on the effectiveness of the Hepatitis C testing program by January 1, 2014. The State Surgeon General must submit the report to the Governor, the President of the Senate, the Speaker of the House of Representatives, and the appropriate substantive committees of the Legislature.

<sup>&</sup>lt;sup>18</sup> Agency for Health Care Administration, 2014 Agency Legislative Bill Analysis - SB 824 (January 2, 2014), on file with Senate Health Policy Committee.

**Section 2** provides an effective date of the act of July 1, 2014.

## IV. Constitutional Issues:

A. Municipality/County Mandates Restrictions:

None.

B. Public Records/Open Meetings Issues:

None.

C. Trust Funds Restrictions:

None.

# V. Fiscal Impact Statement:

## A. Tax/Fee Issues:

SB 824 does not address who would incur the cost of the test if conducted at a CHD or other government facility should the patient not have the means to cover the fees. Currently, the CHDs charge only a small administrative fee for the test and will waive the fee if the patient is unable to pay.

## B. Private Sector Impact:

Certain health care practitioners, as defined under the bill, would be required to offer individuals born between 1945 and 1965 a Hepatitis C screening when they receive health care services in a general hospital, primary care services in an inpatient or outpatient setting or from certain primary care providers. The screening is voluntary, but unless the patient is being treated for an emergency or has already been screened or tested, the health care practitioner would be required to offer the screening.

For health insurers and other insurance carriers, the bill requires that the test be offered; however, it does not mandate that the patient's insurance carrier provide coverage for the test or treatment. However, non-grandfathered health plans and other health insurance coverage are already required to cover any preventive services that receive an "A" or "B" grade from the USPSTF.<sup>19</sup>

## C. Government Sector Impact:

To the extent that local governments operate hospitals or facilities that treat patients in the age cohort, these facilities would be required to offer the Hepatitis C screening except in limited circumstances. The bill does not address who would incur the cost of the test should the patient not have the means to cover the fees. Additionally, if an indigent or

<sup>&</sup>lt;sup>19</sup> See Sec. 2713; Pub. Law No. 111-148, H.R. 3590, 111th Cong. (Mar. 23, 2010) and 29 CFR Section 2590.715-2713.

low income patient is identified with the HCV, it is unclear how a patient without a primary care provider would receive the follow-up health care identified in the bill. New treatments for HCV have been estimated to cost at least \$66,000 to \$84,000.<sup>20</sup>

The DOH reports that the bill could increase demand for its services. During the last calendar year, the CHDs saw 131,821 people born between 1945 and1968.<sup>21</sup> The DOH projects that 70 percent of these individuals had incomes below 100 percent of the federal poverty level, placing them in the "no pay" category of the CHD's fee scale. The DOH was unable to determine the total fiscal impact but stated it may exceed their current resources.<sup>22</sup>

The DOH will also be required to adopt rules for procedures that are culturally and linguistically appropriate as well and report on the effectiveness of the Hepatitis C testing program by January 1, 2016.

The AHCA reports that the potential fiscal impact caused by the possible treatment of additional Medicaid recipients between 49 and 69 years of age is minimal and indeterminate for the following reasons:<sup>23</sup>

- In persons without symptoms, Hepatitis C is often detected through routine blood tests to measure liver function and that treatment is already covered by Medicaid;
- The AHCA cites a World Health Organization report<sup>24</sup> that Hepatitis C does not always require treatment, so it is difficult to predict whether an increase in the number of tests will automatically result in treatment with a variety of medications; and,
- Early detection of asymptomatic patients may result in lower treatment costs in the long-term.

**For Year One**, the AHCA estimates an overall fiscal impact of \$2,180,621, of which \$1,288,747 represents the federal share and the remaining \$891,874 the state costs. The cost impact is based on 50 percent of the eligible population receiving the test and 1.6 percent of those that tested having follow-up tests.

**For Year Two**, the recurring impact estimate is \$1,090,311 (\$647,536 federal share; \$442.775 state share).

## VI. Technical Deficiencies:

A "health care practitioner" is defined on lines 18 through 22 as a physician licensed under chapter 458, an osteopathic physician under chapter 459, or, an advanced registered nurse

<sup>&</sup>lt;sup>20</sup> Julie Appleby, *Should Healthier Patients Be Asked to Wait to Use Costlier Hepatitis C Drugs?*, KAISER HEALTH NEWS, Mar. 11, 2014 at <a href="http://capsules.kaiserhealthnews.org/index.php/2014/03/cost-of-new-hepatitis-c-drugs-ignites-debate-about-who-needs-them-now/">http://capsules.kaiserhealthnews.org/index.php/2014/03/cost-of-new-hepatitis-c-drugs-ignites-debate-about-who-needs-them-now/</a>.

<sup>&</sup>lt;sup>21</sup> Department of Health, *Supra*, note 6 at 5.

<sup>&</sup>lt;sup>22</sup> Department of Health, *Supra*, note 6 at 5.

<sup>&</sup>lt;sup>23</sup> Agency for Health Care Administration, *Supra*, note 18 at 3.

<sup>&</sup>lt;sup>24</sup> World Health Organization, *Hepatitis C - Fact Sheet*, (July 2013), <a href="http://www.who.int/mediacentre/factsheets/fs164/en/">http://www.who.int/mediacentre/factsheets/fs164/en/</a> (last visited Mar. 14, 2014).

practitioner, registered nurse or licensed practical nurse under chapter 464. The term "health care practitioner" is then used throughout the bill. However, on lines 33 through 34 in discussing who may offer a test, a physician, physician assistant or nurse practitioner are specifically named as if the terms were inter-changeable with the earlier definition of a health care practitioner. This creates an apparent conflict about who is a health care practitioner for the purposes of this bill.

On lines 50 through 52, the provision referencing a requirement for the DOH to develop rules, it is not clear what is "culturally or linguistically" being offered. A word appears to be missing or misplaced in this sentence.

## VII. Related Issues:

On lines 45 through 49, the bill requires the health care practitioner to offer the person follow-up care or referral to a health care provider that can provide such follow-up care. The provision also requires that the follow-up care include a Hepatitis C diagnostic test. Both activities are mandatory on the part of the health care practitioner and does not address whether the patient can afford the follow-up care that must be offered or the required diagnostic test, including whether the referring provider might later determine that the diagnostic test is not necessary.

## VIII. Statutes Affected:

This bill creates the following section of the Florida Statutes: 381.0044.

#### IX. Additional Information:

A. Committee Substitute – Statement of Changes:

(Summarizing differences between the Committee Substitute and the prior version of the bill.)

None.

B. Amendments:

None.

This Senate Bill Analysis does not reflect the intent or official position of the bill's introducer or the Florida Senate.